Recent advances of the Ephrin and Eph family in cardiovascular development and pathologies

作者：Yuan Zhu, Sheng-an Su, Jian Shen, Hong Ma, Jixie Le, Yao Xie, Meixiang Xiang · 发表于：iScience · 年份：2024 · DOI：10.1016/j.isci.2024.110556 · 被引用次数：24 · 研究领域：Axon Guidance and Neuronal Signaling、Hippo pathway signaling and YAP/TAZ、Apelin-related biomedical research

Erythropoietin-producing hepatoma (Eph) receptors, comprising the largest family of receptor tyrosine kinases (RTKs), exert profound influence on diverse biological processes and pathological conditions such as cancer. Interacting with their corresponding ligands, erythropoietin-producing hepatoma receptor interacting proteins (Ephrins), Eph receptors regulate crucial events like embryonic development, tissue boundary formation, and tumor cell survival. In addition to their well-established roles in embryonic development and cancers, emerging evidence highlights the pivotal contribution of the Ephrin/Eph family to cardiovascular physiology and pathology. Studies have elucidated their involvement in cardiovascular development, atherosclerosis, postnatal angiogenesis, and, more recently, cardiac fibrosis and calcification, suggesting a promising avenue for therapeutic interventions in cardiovascular diseases. There remains a need for a comprehensive synthesis of their collective impact in the cardiovascular context. By exploring the intricate interactions between Eph receptors, ephrins, and cardiovascular system, this review aims to provide a holistic understanding of their roles and therapeutic potential in cardiovascular health and diseases.